Takeda Pharmaceutical Company Limited (TAK)
| Market Cap | 66.18B +55.9% |
| Revenue (ttm) | 29.86B +6.3% |
| Net Income | 259.59M +23.3% |
| EPS | 0.08 +24.9% |
| Shares Out | 1.60B |
| PE Ratio | 258.56 |
| Forward PE | 19.17 |
| Dividend | $0.24 (1.15%) |
| Ex-Dividend Date | Mar 31, 2026 |
| Volume | 2,968,892 |
| Open | 20.62 |
| Previous Close | 21.19 |
| Day's Range | 20.57 - 21.09 |
| 52-Week Range | 13.56 - 21.73 |
| Beta | 0.10 |
| Analysts | Strong Buy |
| Price Target | 22.99 (+9.37%) |
| Earnings Date | Oct 29, 2026 |
About TAK
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enan... [Read more]
Analyst Summary
According to 3 analysts, the average rating for TAK stock is "Strong Buy." The 12-month stock price target is $22.99, which is an increase of 9.37% from the latest price.
News
Friday's ETF Movers: PPH, PSI
In trading on Friday, the VanEck Pharmaceutical ETF is outperforming other ETFs, up about 2.4% on the day. Components of that ETF showing particular strength include shares of Astrazeneca, up about 7....
What Takeda Pharmaceutical (TAK) Said on Its Q2 Earnings Call
Takeda Pharmaceutical NYSE: TAK reported first-half fiscal 2026 results that management said were in line with expectations as the company invested in new product launches and its late-stage pipeline ...
Takeda Pharmaceutical Company Limited Reports JPY 2,406,997 Million Revenue for the Six-Month Period Ended September 30, 2026
Takeda Pharmaceutical Company Limited reported revenue of JPY 2,406,997 million for the six-month period ended September 30, 2026, representing an increase from JPY 2,219,481 million in the same perio...
Takeda Pharmaceutical Company Limited Reports Revenue of 2,406,997 Million JPY for the Six-month Period Ended September 30, 2026
Takeda Pharmaceutical Company Limited reported revenue of 2,406,997 million JPY and operating profit of 406,739 million JPY for the six-month period ended September 30, 2026. This represents a revenue...
Takeda H1 EPS Surges, Revenue Up 8.4%; Upgrades FY26 Outlook
(RTTNews) - Takeda Pharmaceutical Company Ltd. (TAK), Thursday reported a 171.8 percent surge in first half earnings compared to the prior year. Looking ahead to the full year 2026, the company raised...
Takeda Pharmaceutical Company Earnings Call Transcript: Q2 2027
H1 FY2026 core revenue declined 1% at CER, while core operating profit grew 0.7%, supported by transformation savings. Launches and pipeline progress advanced; full-year profit guidance rose mainly on FX, while mature-portfolio and reimbursement headwinds persist.
Takeda Pharmaceutical Company Quarterly report: Q2 2027
Takeda Pharmaceutical Company has published its Q2 2027 quarterly earnings report on October 29, 2026.
Takeda Pharmaceutical Company Slides: Q2 2027
Takeda Pharmaceutical Company has posted slides in relation to its Q2 2027 quarterly earnings report, which was published on October 29, 2026.
Takeda Pharmaceutical Company Earnings release: Q2 2027
Takeda Pharmaceutical Company released its Q2 2027 earnings on October 29, 2026, summarizing the period's financial results.
Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced financial results for the first half of fiscal year 2026 (April 1, 2026, to Sept. 30, 2026). The period included the approval of O...
Takeda to seek Japan approval for gastric cancer drug next year
Takeda Pharmaceutical plans to seek regulatory approval in Japan next year for its gastric cancer drug, after it extended overall survival and delayed disease progression in a late-stage study, a comp...
Takeda announces Phase 3 G-HOPE-001 study met primary endpoints
Takeda (TAK) announced positive results from the Phase 3 G-HOPE-001 study of arcotatug tavatecan in patients with Claudin18.2-positive, previously treated, advanced gastric or gastroesophageal junctio...
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D co...
Takeda's ENTYVIO Treat-To-Target Trial Reduces UC Complication Risk By Nearly 70%; Stock Down
(RTTNews) - Takeda Pharmaceutical Company Limited (TAK) announced results from the Phase 4 VERDICT trial showing that treating adults with moderate to severe ulcerative colitis (UC) with ENTYVIO (vedo...
Takeda Reports Positive New Data Of VERDICT Phase 4 ENTYVIO Trial In Ulcerative Colitis
(RTTNews) - Japan's Takeda Pharmaceutical Co. Ltd. (TAK,4502.T) announced Monday positive new data from VERDICT (NCT04259138), a Phase 4 ENTYVIO clinical trial, in ulcerative colitis or UC-related com...
First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achi...
Takeda Launches ORZEYFUL For Narcolepsy Type 1 In Japan, China; Stock Up
(RTTNews) - Takeda Pharmaceutical Company Ltd. (TAK,4502.T), which explores orexin science, announced on Thursday that ORZEYFUL (oveporexton) is now available in Japan and China to treat Narcolepsy Ty...
Takeda’s ORZEYFUL launches in Japan and China
Takeda (TAK) “announced that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with…
Takeda's ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1...
Takeda's TAK-881 Cuts Infusion Time By 42.6% In Phase 3 PID Study
(RTTNews) - Takeda Pharmaceutical Company Limited (TAK), a biopharmaceutical company developing treatments for rare diseases and other conditions, presented detailed Phase 2/3 IgGNITE study results fo...
Takeda announces Phase 2/3 IgGNITE trial met primary endpoint
Takeda (TAK) announced detailed results from the Phase 2/3 IgGNITE clinical trial, TAK-881-3001, evaluating investigational TAK-881, which, if approved, has the potential to become the first facilitat...
Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda presents Phase 2/3 study results for TAK-881 in primary immunodeficiency (PID), showing comparability to HYQVIA with 50% less IG volume.
Takeda reports new data from Phase 3 LATITUDE psoriasis studies of zasocitinib
Takeda (TAK) announced new data from three Phase 3 LATITUDE psoriasis studies of zasocitinib, an investigational, next-generation, highly selective and potent oral tyrosine kinase 2, or TYK2, inhibito...
Takeda reports new data from Phase 3 LATITUDE psoriasis studies of zasocitinib
Takeda (TAK) announced new data from three Phase 3 LATITUDE psoriasis studies of zasocitinib, an investigational, next-generation, highly selective and potent oral tyrosine kinase 2, or TYK2, inhibito...
Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced new data from three Phase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279), an investigational, next-generat...